compound might act to modulate the cell cycle regardless of p53 status. In addition, LQB-223 resulted in decreased procaspase levels and increased annexin V staining, suggesting that the apoptotic cascade is also triggered. Importantly, LQB-223 treatment was shown to be less cytotoxic to non-neoplastic breast cells than docetaxel and doxorubicin. Strikingly, exposure of doxorubicin-resistant MCF-7-Dox R cells to LQB-223 resulted in suppression of cell viability and proliferation in levels comparable to MCF-7. Of note, MCF-7-Dox R cells have an elevated expression of the P-glycoprotein efflux pump when compared to MCF-7. Conclusion Together, these results show that LQB-223 mediates cytotoxic effects in sensitive and resistant breast cancer cells, while presenting low toxicity to non-neoplastic cells. The new compound might represent a potential strategy to induce toxicity in breast cancer cells, especially chemoresistant cells.
Introduction
Human breast tumors are phenotypically heterogeneous and are associated with different clinical outcomes, accounting for high mortality rates in women worldwide (Curtis et al. 2012; Perou et al. 2000) . Treatment of breast cancer involves several modalities such as surgery, radio-, chemo-, targeted-and hormonal therapy (Chargari et al. 2009 ). Doxorubicin (DOX) and docetaxel (DTX) are chemotherapeutic agents commonly used for several types of malignancies, including breast cancer (Burnell et al. 2010) . DOX belongs to the anthracyclines class, and some of its antitumor mechanisms of action include DNA Abstract Multidrug resistance is the major obstacle for successful treatment of breast cancer, prompting the investigation of novel anticancer compounds. Purpose In this study, we tested whether LQB-223, an 11a-N-Tosyl-5-deoxi-pterocarpan newly synthesized compound, could be effective toward breast cancer cells. Methods Human breast cell lines MCF-7, MDA-MB-231, HB4a and MCF-7 Dox R were used as models for this study. Cell culture, MTT and clonogenic assay, flow cytometry and Western blotting were performed. Results The LQB-223 decreased cell viability, inhibited colony formation and induced an expressive G2/M arrest in breast cancer cells. There was an induction in p53 and p21
Cip1 protein levels following treatment of wild-type p53 MCF-7 cells, which was not observed in the mutant p53 MDA-MB-231 cell line, providing evidence that the Electronic supplementary material The online version of this article (doi:10.1007/s00432-016-2212-6) contains supplementary material, which is available to authorized users. intercalation, DNA damage mediated by reactive oxygen species, inhibition of topoisomerase (topo) II alpha and beta and activation of apoptotic pathways (Lyu et al. 2006; Zhang et al. 2012) . However, patients treated with DOX may present some side effects, such as cardiotoxicity (Azim et al. 2011; Bird and Swain 2008; Swain et al. 2003) and acute events such as stomatitis, neutropenia, hematologic toxicity and myelosuppression. In long term, some patients may develop secondary leukemia, necrosis at the injection site, liver injury and hypersensitivity (Panis et al. 2012) . DTX belongs to the family of taxanes and has been used as neoadjuvant or adjuvant treatment of breast cancer in association with anthracyclines (Burnell et al. 2010) . Its mechanism of action involves stabilization of microtubules by binding with β-tubulin, which leads to an arrest in G2/M phase and induction of cell death (Murray et al. 2012; Shalli et al. 2005) . It was reported that taxanes induce systemic changes in the oxidative stress profile of hematopoietic cells of breast cancer patients, resulting in anemia (Panis et al. 2012) . Another important aspect related to the use of DOX and DTX relates to the fact that many patients will eventually develop resistance to these drugs, which is the major obstacle to successful treatment (Kumler et al. 2015; Murray et al. 2012) . Therefore, the identification of novel compounds that might circumvent mechanisms of drug resistance in breast cancer and exhibit lower toxicity is crucial. Some hybrid compounds between pterocarpans and quinones, named pterocarpanquinones, have been synthesized and had their antineoplastic activity studied in tumor cell models (Buarque et al. 2011) . Recently, the LQB-223, an 11a-N-Tosyl-5-deoxi-pterocarpan compound, has been synthesized and shown to induce cytotoxicity in drug-resistant leukemia cells (Buarque et al. 2014 ). Here, we investigated the antitumor effects of LQB-223 synthetic compound in human breast cancer cell lines and found that it impairs cell viability, induces apoptotic cell death and modulates signaling pathways involved in cell cycle control. Interestingly, the LQB-223 compound showed also pronounced cell viability and proliferation inhibition in P-glycoprotein (Pgp) overexpressing DOXresistant cells, suggesting that it can overcome drug resistance in breast cancer. Most importantly, we observed little cytotoxicity toward non-neoplastic breast cells which might point LQB-223 as a promising compound for treatment of breast tumors.
Materials and methods

Drugs
The 11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, was synthesized in the Laboratório de Química Bioorgânica, at Universidade Federal do Rio de Janeiro (UFRJ) as described previously (Buarque et al. 2014) . The compound was dissolved in dimethyl sulfoxide (DMSO) and used at 1, 2.5, 5, 10, 15 and 20 μM concentrations. DOX (doxorubicin; Rubidox ® ) and DTX (docetaxel, Docelibbs ® ) was provided by Bergamo and Libbs, respectively (São Paulo, Brazil). Dilutions from stock solutions were made prior to use and kept at −20 °C. Final concentrations used for most experiments were 1 μM DOX and 100 nM DTX, since these doses were shown to be clinically relevant (Gewirtz 1999; Hernandez-Vargas et al. 2007 ).
Cell lines
The human mammary epithelial cell lines MCF-7 (invasive breast ductal carcinoma, wild-type p53, estrogen and progesterone receptors positive, and Her2/neu overexpression negative), MCF-7 Dox R (DOX-resistant cell line derived from parental MCF-7) (Millour et al. 2011 ), MDA-MB-231 (invasive breast ductal carcinoma, mutant p53, estrogen, progesterone and Her2 receptors negative) and HB4a (originated from luminal breast cells, negative for estrogen and progesterone receptors and expresses basal levels of HER-2 receptor) (Stamps et al. 1994; Trape et al. 2012) were used as models for this study. The cell lines were cultured in Dulbecco's modified Eagle's medium (Gibco; BRL, UK), supplemented with 10 % heat-inactivated FBS (Gibco) and penicillin/streptomycin (1 µL/mL) concentration. The HB4a cell line was also cultured with 5 µM hydrocortisone and insulin. The cell lines were maintained in a humidified atmosphere at 37 °C and 5 % CO 2 .
Measurement of cell metabolic viability
After seeding and 24 h adherence, 1 × 10 4 cells were treated with LQB-223, DOX and DTX for 24, 48 and 72 h and were submitted to the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Mosmann 1983) . Absorbance at 492 nm was measured with an ELISA reader (DTX 800 Multimode Detector from Beckman Coulter, Fullerton, CA, USA). The concentrations and experiments were conducted in triplicate. This assay was performed for measurement of drug-mediated changes in cell viability.
Clonogenic assay
A total of 2 × 10 3 cells were seeded in 6-well plates and then left to adhere overnight and then treated with LQB-223, DOX or DTX. After 24 h, drugs were removed and the cells were maintained in drug-free media for about 14 days, until colony formation. Colonies were fixed in absolute ethanol and stained with 0.05 % crystal violet. The crystals were diluted in 33 % glacial acetic acid solution, and the optical density was measured at 595 nm.
Cell cycle analysis
A total of 5 × 10 5 cells were left to adhere onto tissue flasks and exposed to LQB-223, DOX or DTX for 24, 48 and 72 h. Then, cells were harvested by trypsinization, and the DNA content was analyzed following addition of 50 µg/ mL Propidium Iodide (PI) and ribonuclease A (100 µg/ mL). Fluorescence was measured by flow cytometry using a CyAn ADP (Beckman Coulter Inc; Brea, CA, US).
Cell death assay
The cells were left to adhere, and LQB-223, DTX or DOX were added and maintained for 24, 48 and 72 h. Cells were submitted to trypsinization, washed in 2 % PBS/BSA (phosphate buffered saline with bovine serum albumin) and centrifuged for 3 min at 770 g. Following 30 min of incubation in 2 % PBS/BSA, cells were centrifuged and the pellets were incubated with 5 μg/ml Annexin V-Alexa Fluor 488 (Life Technologies; Carlsbad, California, EUA), and binding buffer for 15 min, after 5 μg/ml propidium iodide (PI) was added. The annexin V and PI fluorescence were measured by flow cytometry using a CyAn ADP (Beckman Coulter Inc; Brea, CA, US).
Western Blotting
For analysis of p53, p21
Cip1 and procaspases expression, pellets of 2 × 10 6 were washed three times in PBS, lysed in Cell Extraction Buffer from Invitrogen (Eugene, OR, Carlsbad, CA, US) and quantified using the Bio-Rad protein assay solution (Life Science Research, Hercules, CA, US). Western blotting was performed as previously described (Nestal de Moraes et al. 2014) . Antibodies for procaspase-7 and -9 were purchased from R&D Systems (1:1000 dilution; Minneapolis, MN, USA), p53 from Dako cytomation Denmark A/S (1:500 dilution), procaspase-3, from BD Biosciences (1:1000 dilution; San Jose, CA, USA), and p21 from Cell Signaling (1:1000 dilution; Danvers, MA, USA). β-actin primary and mouse and rabbit secondary antibodies were purchased from Sigma-Aldrich (1:5000, 1:160,000 and 1:120,000 dilution, respectively; St Louis, MO, USA). HSC70 (1:500 dilution; Santa Cruz, CA, US) and β-actin were used as loading controls. Caspase activation was estimated by reduction of procaspase-3, -7 and -9 levels.
P-glycoprotein (Pgp) expression by flow cytometry
To compare Pgp membrane expression in MCF-7 and MCF-7 Dox R cell lines, a total of 5 × 10 5 cells were stained with anti-Pgp antibody (clone UIC2, Coulter, USA) and analyzed through flow cytometry as previously described by our group (Vasconcelos et al. 2011) .
Statistical analysis
Statistical analysis of data was conducted using the GraphPad Prism 5.0 (GraphPad Software, San Diego, USA). The paired Student's t test was used to compare differences between means from two groups.
Results
LQB-223 compound presents antitumour effects toward breast cancer cells and is less cytotoxic to non-neoplastic breast cells than docetaxel and doxorubicin
First, we evaluated whether LQB-223 compound could promote changes in cell viability in MCF-7 and MDA-MB-231 cell lines. We observed that the treatment of MCF-7 and MDA-MB-231 cell lines with LQB-223 resulted in decreased cell viability in a time-dependent manner (Fig. 1a, b and Online Resource 3 Tables 1 and 2 ).
In MCF-7 cell line, there was a significant decrease in cell viability with 5 μM at 48 h incubation ( Fig. 1a and Online Resource 3 Table 1 ). In MDA-MB-231 cells, the cell viability decrease at 20 μM LQB-223 was the most significant ( Fig. 1b and Online Resource 3 Table 2 ). Besides, we observed morphological alterations when MCF-7 and MDA-MB-231 cells were treated with LQB-223 for 48 h (Online Resource 1a-b), reinforcing the cytotoxic properties of LQB-223. It has been widely shown that DTX and DOX treatment causes side effects to cancer patients, particularly because these drugs are cytotoxic not only to tumor cells, but also to normal tissues. Therefore, we tested whether LQB-223 compound would present lower cytotoxic to HB4a nonneoplastic breast cells compared to DTX and DOX. We did not observe any inhibition in cell viability after LQB-223 treatment, while DOX and DTX displaced significant cytotoxicity ( Fig. 1c and Online Resource 3 Table 3 ). In addition, we could not observe pronounced morphological changes when HB4a cells were treated with LQB-223 for 48 h (Online Resource 2).
Then, we evaluated cell proliferation and LQB-223 compound reduced colony formation in both breast cancer cell lines, demonstrating its ability to inhibit cell proliferation (Fig. 2a, b) . Although LQB-223 effect on proliferation was lower than DOX and DTX, there was a 50 % inhibition in colony formation. These results indicate that treatment with LQB-223 can efficiently reduce the viability 1 3 and proliferation of breast cancer cells. We have also observed a decrease in cell proliferation in non-neoplastic breast cells (Fig. 2c) . Nevertheless, the decrease induced by LQB-223 was significantly less important to non-neoplastic breast cells than the decrease induced by treatment with the drugs conventionally used in the clinic scenario such as DTX and DOX (p < 0001). These results suggest that LQB-223 induces low toxicity to non-neoplastic breast cells when compared to drugs currently used to treat breast cancer.
LQB-223 induces G2/M arrest to inhibit proliferation in breast cancer cells
Since our results showed that LQB-223 inhibited cell proliferation in MCF-7 and MDA-MB-231 cells, we wondered if the compound could change the cell cycle profile. We found that there was a pronounced increase in the percentage of cells in G2/M phase at all time points and in both cell lines, MCF-7 and MDA-MB-231 (Fig. 3a,  b) . Interestingly, this effect was comparable to the one Fig. 1 LQB-223 observed after 100 nM DTX exposure. Also, we observed that there was an increase in the sub-G0/G1 population over time, especially in MCF-7 cells, suggesting induction of cell death by the compound. Similarly, to DOX and DTX treatment of MDA-MB-231 cell line, we found that LQB-223 exposure led to an increased number of hyperdiploidic cells (Fig. 3b) . These data indicate that LQB-223 might inhibit cell proliferation through impairing cell cycle progression.
LQB-223 compound acts irrespective of p53 status
In order to elucidate the mechanisms involved in G2/M cell cycle arrest caused by LQB-223 treatment, we Fig. 2 Colony formation following LQB-223 treatment was assessed by the clonogenic assay. a MCF-7, b MDA-MB-231 and c HB4a were treated with LQB-223, DTX and DOX for 24 h, after which the drug was removed. After colony formation, cells were stained with crystal violet. Colonies were dissolved and optical density was measured. The graphs represent the mean ± standard deviation from three independent experiments. UT Untreated cells, DMSO Dimethyl sulfoxide, DTX Docetaxel, DOX Doxorubicin. Statistical significance was analyzed by the Student's t test (*p < 0.05; **p < 0.01; ***p < 0.001) 1 3 investigated the expression levels of p53 and p21 proteins. The p21
Cip1 protein is regulated by p53 in response to DNA damage (Ho et al. 2015) . These proteins are important negative cell cycle regulators and influence the formation of cyclin/CDK complexes, which are essential for cell cycle progression (el-Deiry et al. 1993; Prives 1993; Xiong et al. 1993) . MCF-7 cell line showed increased p53 and p21
Cip1 protein expression when cells were treated with 5 and 20 µM of LQB-223 at 48 h, suggesting that the compound can activate p53 expression in breast cancer cells presenting its wild-type functional form. Since p53 protein is quickly degraded, its activation status is reversed (Fig. 4a) . In MDA-MB-231 cell line, which presents the mutant form of p53, there was no modulation in p53 expression, not even in the levels of p21, its transcriptional target (Fig. 4b) . These data show that LQB-223 can inhibit proliferation in breast cancer cells regardless of the p53 status.
The antineoplastic activity of LQB-223 on breast cancer cells also relies on its ability to induce apoptotic cell death
After establishing that LQB-223 induces G2/M cell cycle arrest and acts by p53 independent mechanisms, the next step was to investigate if the compound could induce apoptosis in breast cancer cells. We observed that LQB-223 treatment induced an increase in the percentage of Annexin V positivity in MCF-7 and MDA-MB-231 cells (Fig. 5a,  b) . To confirm this finding, we analyzed procaspases levels and found that there was a decrease of procaspases -and -9 levels in MCF-7 (Fig. 5c) and -3 and -7 in MDA-MB-231 cells (Fig. 5d ) after 72 h of LQB-223 treatment. Our findings suggest that LQB-223 induces its cytotoxic effects by triggering apoptotic cell death.
LQB-223 is effective toward P-glycoprotein overexpressing doxorubicin-resistant cells
To further analyze whether LQB-223 would be effective against drug-resistant tumors, we studied its effects in the MCF-7 Dox R cell line, a doxorubicin-resistant model originally derived from MCF-7 cells (Millour et al. 2011 ). These cells were originally resistant to DOX, but also developed cross-resistance to DTX (Fig. 6a) . Our results showed that LQB-223 inhibited cell viability in a dose and time-dependent manner ( Fig. 6a and Online Resource 3 Table 4 ). Remarkably, the compound was more effective in suppressing cell viability in MCF-7 Dox R than in its parental MCF-7 cell line (Fig. 6b) . Furthermore, LQB-223 suppressed colony formation in MCF-7 Dox R cells as evaluated by the clonogenic assay, while this effect was not observed following DOX and DTX treatment (Fig. 6c) . These results indicate that LQB-223 is a potent compound toward drug-resistant breast cancer cells. It is important to highlight that MCF-7 Dox R cells present high levels of Pgp expression (Fig. 6d) , a drug transporter well known to be overexpressed in drug-resistant tumor cells and to be closely linked to the development of the resistance phenotype (Kim et al. 2015; Trock et al. 1997) .
Discussion
Breast cancer is the most frequent and one of the highest mortality-related malignancies in women worldwide (www. who.int/en). One of the causes of high mortality rates is the resistance to chemotherapy shown by many patients (Holohan et al. 2013 ) and has been demonstrated in vitro since the 90s by Chen et al. (1990) . Different mechanisms are involved in resistance to anthracyclines and taxanes. An important common mechanism to both treatments is the increased expression of Pgp, a drug efflux pump related to cross-resistance (Chintamani et al. 2005; Trock et al. 1997) . Beyond that, treatment with chemotherapeutics has high toxicity for patients, therefore reducing their quality of life (Panis et al. 2012; Smith et al. 2010) .
In order to improve the efficacy of patients' treatment with more effective and less toxic drugs, it is of great relevance to study the effect of new antineoplastic compounds. In our laboratory, many compounds, such as LQB-118, have been synthesized by Netto et al. (2010) and displayed potent activity against leukemia (de Faria et al. 2015; de Souza Reis et al. 2013; Maia et al. 2011; Nestal de Moraes et al. 2014) , and prostate cancer cells displaying a resistant phenotype (Martino et al. 2014) . However, when LQB-118 compound was tested in breast cancer cells, no viability change was observed (data not shown). Despite this, other pterocarpan-based compounds presented antineoplastic 5 Antineoplastic activity of LQB-223 on breast cancer cells also relies on its ability to induce apoptotic cell death. a MCF-7 and b MDA-MB-231 were treated with LQB-223 for 24, 48 and 72 h and analyzed for annexin V/PI staining by flow cytometry. c and d alternatively, the cell lines were exposed to LQB-223 for 72 h and procaspase levels were evaluated by Western blotting. The graphs represent the mean ± standard deviation from three independent experiments. UT Untreated cells, DMSO Dimethyl sulfoxide. Statistical significance was analyzed by the Student's t test (*p < 0.05; **p < 0.01; ***p < 0.001) effects on leukemic cell lines, colon cancer, glioblastoma and melanoma (Buarque et al. 2011) . Recently, the LQB-223 was designed by molecular hybridization from LQB-118 (Buarque et al. 2013 ). This compound was synthesized and demonstrated cytotoxicity regardless of the resistance phenotype in leukemia cells (Buarque et al. 2014 ).
Here, we observed that the LQB-223 compound reduced cell viability and proliferation of neoplastic breast cell lines with different resistance/sensitivity phenotypes. The compound was also selective for tumor cell lines, as it did not decrease cell viability in human breast non-neoplastic cell line, HB4a. Moreover, in the clonogenic assay, DTX R and MCF-7 cells were treated with LQB-223 compound for 72 h and changes in cell viability were analyzed by MTT assay. c MCF-7 Dox R cells were treated with LQB-223, DOX and DTX for 24 h, after which the drug was removed. After colony formation, cells were stained with crystal violet. Colonies were dissolved, and optical density was measured. d MCF-7 Dox R and MCF-7 cells had Pgp (P-glycoprotein) expression analyzed by flow cytometry. The histograms are representative of three independent experiments. UT Untreated cells, DMSO Dimethyl sulfoxide, DTX Docetaxel, DOX Doxorubicin. Statistical significance was analyzed by the Student's t test (*p < 0.05; **p < 0.01; ***p < 0.001) and DOX reduced cell proliferation more significantly than LQB-223 in the HB4a cells. Buarque and colleagues (Buarque et al. 2014 ) also demonstrated the selectivity of LQB-223 as it had cytotoxic effects to leukemia cells and no toxicity to ex vivo cultured lymphocytes derived from mice's spleen.
The clonogenic assay results prompted us to analyze the cell cycle profile and significant arrest in G2/M cell cycle phase was observed when MCF-7 and MDA-MB-231 cells were treated with LQB-223. MCF-7 cells have a doubling time of 36 h, while MDA-MB-231 and MCF-7 Dox R cells duplicate in 48 h. Comparing only MCF-7 and MDA-MB-231 cells, we could suppose that LQB-223 cytotoxic effects are more pronounced in MCF-7 due to its shorter duplication time (and thus, higher proliferative rates), which would make them more susceptible to a cytotoxic compound. However, our results demonstrated that LQB-223 showed more cytotoxicity toward dox-resistant MCF-7 Dox R than MCF-7 and MDA-MB-231 cells, which suggest that the effects of LQB-223 on breast cancer cells do not depend only on their doubling time. In addition, we extended our cell cycle experiments to 72 h, so that all cell lines could be assessed for DNA content at least after one round of duplication. In accordance with our results, Buarque and colleagues (Buarque et al. 2014 ) observed cell cycle arrest and hyperdiploidy induced by LQB-223 in leukemia cell lines. It is well known that cell cycle is regulated by cyclin-CDK complexes (Sherr 1993; Weinberg 1995) and, specifically in the G2/M phase, modulation of cyclin B/CDK1 complex plays a major role. In this context, p21 binds to cyclin-CDK complexes (Xiong et al. 1993 ) and inhibits CDK kinase activity, playing an important role in the regulation of cell cycle checkpoints, including G2/M. p21 is regulated by p53 in response to DNA damage (el-Deiry et al. 1993; Ho et al. 2015; Prives 1993; Xiong et al. 1993) . In this study, we observed the occurrence of cell cycle modulation in both cell lines, but p53 and p21 regulation after LQB-223 treatment was found only in MCF-7 cells harboring wild-type p53. This could be explained by the fact that MDA-MB-231 cells have functional p73 expression, which may partially assume p53 functions in p53-unfunctional cells (Vayssade et al. 2005; Wong et al. 2011) . Overall, our results might suggest that LQB-223 cytotoxic effects do not depend upon p53 status, an observation quite important in the context of a disease with a high frequency of TP53 gene mutations (BorresenDale 2003) .
As a consequence of cell cycle arrest at G2/M, other cellular pathways can be activated, inducing apoptosis (Prives 1993; Zhou and Elledge 2000) . Therefore, we demonstrated that LQB-223 induces apoptosis by detecting annexin V labeling and reduction in the procaspase-3, -7 and -9 levels. LQB-223 induces cytotoxic effects, reduces cell viability and proliferation by mechanisms related to cell cycle arrest, ending in apoptotic cell death of breast cancer cells. The activation of apoptosis is a common mechanism among the chemotherapeutics studied, DTX and DOX (Ling et al. 1993; Shalli et al. 2005) . However, many patients present chemotherapy resistance, which are eventually closely linked to reduced apoptotic indexes. An important mechanism involved in the resistance to DTX is alterations in β-tubulin isotypes expression (Greenberger et al. 1987; Shalli et al. 2005) and to DOX is topoisomerase II alterations and p53 mutations (Chernov and Stark 1997; Knappskog et al. 2015; Larsen and Skladanowski 1998) . Because it is not likely that the LQB-223 cytotoxic compound acts the same way as DOX or DTX, it may represent a potential activator of apoptosis independently of these mechanisms of resistance.
Additionally, we observed viability and proliferation reduction in the resistant cell line, MCF-7 Dox R , after LQB-223 treatment, which was remarkably more effective than DTX and DOX. Interestingly, the MCF-7 Dox R cell line presents cross-resistance to DTX, a phenomenon commonly observed in patients who receive both drugs as treatment (Riordan and Ling 1985) , providing an interesting model to study drug resistance. The cross-resistance and the multidrug resistance (MDR) are related to increased expression and activity of drug efflux pumps, most commonly Pgp (Chintamani et al. 2005; Gottesman et al. 2002; Volk et al. 2000; Zgurskaya and Nikaido 2000) and has been demonstrated in several cancer types (Liu et al. 2015; Turk et al. 2009; Vasconcelos et al. 2011 ). Many strategies have been developed to target Pgp, leading to drug accumulation inside the cell (Kumler et al. 2015; Turk et al. 2009 ). In breast cancer cells, the blockage of Pgp expression conferred more susceptibility to drugs (Linn et al. 1997; Yu et al. 1991) . In order to understand cross-resistance in MCF-7 Dox R cells, we measured the expression of Pgp and demonstrated that these cells exhibited high levels of the efflux pump. This result points out Pgp as an important factor involved in cross-resistance, corroborating the high cellular viability and proliferation observed when MCF-7 Dox R cells were treated with DTX and DOX. Interestingly, it was observed MCF-7 Dox R cells hypersensitivity to LQB-223 which suggests collateral sensitivity. Tumor cells expressing Pgp exhibits increased susceptibility to drug compared to parental cell line (Szakacs et al. 2014) .
Our findings indicate that LQB-223 compound inhibits cell viability, promotes caspase-mediated apoptosis and induces G2/M arrest in breast cancer cell lines derived from different subtypes, irrespective of p53 status. Furthermore, the compound leads to decreased viability and proliferation in resistant breast cancer cell lines. This study provides insights into the mechanisms by which LQB-223 selectively targets cancer cells and points it as a promising compound against breast neoplastic cells, particularly in tumors bearing the multidrug resistance phenotype.
